Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pacira Pharmaceuticals (PCRX – Research Report), Galmed Pharmaceuticals (GLMD – Research Report) and Rani Therapeutics Holdings (RANI – Research Report).
Pacira Pharmaceuticals (PCRX)
Needham analyst Serge Belanger maintained a Buy rating on Pacira Pharmaceuticals today and set a price target of $63.00. The company’s shares closed last Thursday at $38.50, close to its 52-week low of $37.69.
According to TipRanks.com, Belanger is a 2-star analyst with an average return of
Pacira Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $67.88, implying a 77.2% upside from current levels. In a report issued on January 4, Jefferies also maintained a Buy rating on the stock with a $54.00 price target.
See today’s best-performing stocks on TipRanks >>
Galmed Pharmaceuticals (GLMD)
H.C. Wainwright analyst Ed Arce maintained a Hold rating on Galmed Pharmaceuticals today. The company’s shares closed last Thursday at $0.80.
According to TipRanks.com, Arce is a 5-star analyst with an average return of
Galmed Pharmaceuticals has an analyst consensus of Hold.
Rani Therapeutics Holdings (RANI)
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Rani Therapeutics Holdings today and set a price target of $22.00. The company’s shares closed last Thursday at $6.66, close to its 52-week low of $5.11.
According to TipRanks.com, Kapoor is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rani Therapeutics Holdings with a $20.25 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PCRX:
- Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million
- Pacira price target lowered to $50 from $54 at Cowen
- Pacira sinks after continuing to not provide outlook with monthly sales
- Pacira reports preliminary net product sales of $57.5M for November
- Paulson adds Rumble, exits Occidental in Q3